1
|
Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol 2011; 6:1863-81. [PMID: 21142861 DOI: 10.2217/fon.10.142] [Citation(s) in RCA: 269] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The influence of psychosocial factors on the development and progression of cancer has been a longstanding hypothesis since ancient times. In fact, epidemiological and clinical studies over the past 30 years have provided strong evidence for links between chronic stress, depression and social isolation and cancer progression. By contrast, there is only limited evidence for the role of these behavioral factors in cancer initiation. Recent cellular and molecular studies have identified specific signaling pathways that impact cancer growth and metastasis. This article provides an overview of the relationship between psychosocial factors, specifically chronic stress, and cancer progression.
Collapse
Affiliation(s)
- Myrthala Moreno-Smith
- Department of Gynecologic Oncology, UTMD Anderson Cancer Center, 1155 Herman Pressler, Houston, TX 77030, USA
| | | | | |
Collapse
|
2
|
Sanders VM. Adrenergic receptors on T and B lymphocytes: Evidence, function, and clinical implications. ACTA ACUST UNITED AC 2006. [DOI: 10.1016/j.cnr.2006.05.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Lysle DT, How T. Heroin modulates the expression of inducible nitric oxide synthase. IMMUNOPHARMACOLOGY 2000; 46:181-92. [PMID: 10741899 DOI: 10.1016/s0162-3109(99)00172-1] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The use of heroin (diacetylmorphine) is associated with a high incidence of infectious disease, and the immunologic alterations responsible for heroin-induced changes in resistance to infection have not been well characterized. The present study tests the hypothesis that expression of inducible nitric oxide synthase (iNOS) is modulated by the administration of heroin. The initial study using rats showed that heroin administration (0, 0.01, 0.1, or 1.0 mg/kg s.c.) results in a pronounced reduction in lipopolysaccharide (LPS)-induced expression of iNOS mRNA in spleen, lung, and liver tissue as measured by RT-PCR. Heroin also produced a reduction in the level of plasma nitrite/nitrate, the more stable end-product of nitric oxide degradation. In a subsequent study, administration of the opioid receptor antagonist, naltrexone (0.1 mg/kg) prior to the injection of heroin (1.0 mg/kg) blocked the heroin-induced reduction of iNOS expression and plasma nitrite/nitrate levels indicating that the effect is mediated via the opioid-receptor. This study provides the first evidence that heroin induces an alteration of iNOS expression, and suggests that a reduction in nitric oxide production may be involved in the increased incidence of infectious diseases amongst heroin users.
Collapse
Affiliation(s)
- D T Lysle
- Department of Psychology, University of North Carolina at Chapel Hill, 27599-3270, USA.
| | | |
Collapse
|
4
|
Pál E, Yamamura T, Tabira T. Autonomic regulation of experimental autoimmune encephalomyelitis in IL-4 knockout mice. J Neuroimmunol 1999; 100:149-55. [PMID: 10695725 DOI: 10.1016/s0165-5728(99)00209-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The effect of chemical sympathectomy induced with 6-hydroxydopamine (OHDA) on experimental autoimmune encephalomyelitis (EAE) was studied in wild type and IL-4-/- C57BL/6 (B6) mice. When actively sensitized with myelin oligodendrocyte glycoprotein (MOG)35-55 peptide, control B6 mice developed a mild form of EAE with full recovery. The sympathectomized mice developed paralysis with higher maximum disease score and did not recover completely, indicating that the sympathetic nervous system (SNS) down-modulates the process of EAE. Unexpectedly, however, sympathectomy resulted in suppression of EAE in IL-4-/- mice, implying that control of actively induced EAE by the SNS depends on the genetic background of mice. We also induced EAE by passive transfer of MOG35-55-reactive lymph node cells, and this disease was augmented by sympathectomy in both wild type and knockout animals. Further experiments showed that changes in T cell populations and the activity of antigen presenting cells might be responsible for the altered immune response and clinical course after sympathetic ablation. Our studies indicate that the absence of a single cytokine can severely alter nervous-immune system interactions.
Collapse
Affiliation(s)
- E Pál
- Division of Demyelinating Disease and Aging, National Institute of Neuroscience, Tokyo, Japan
| | | | | |
Collapse
|
5
|
Rouppe van der Voort C, Kavelaars A, van de Pol M, Heijnen CJ. Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes. J Neuroimmunol 1999; 95:165-73. [PMID: 10229127 DOI: 10.1016/s0165-5728(99)00011-9] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Beta2- and alpha2-adrenergic receptors (AR) are thought to be the main AR subtypes to exert the effects of catecholamines on the immune system. However, in the present study, we demonstrate that another subtype of AR can be induced in human monocytes. Expression of alpha1b- and alpha1d-AR mRNA can be obtained by culturing freshly isolated human peripheral blood monocytes with the neuroendocrine mediators dexamethasone or the beta2-AR agonist terbutaline. Using the human monocytic cell line THP-1, we demonstrate that increased levels of alpha1b- and alpha1d-mRNA are accompanied by increased levels of receptor protein as determined by Western blot analysis and radioligand binding assays. This study describes for the first time regulated expression of alpha1-AR subtypes in human monocytes.
Collapse
MESH Headings
- Adrenergic beta-Agonists/pharmacology
- Blotting, Western
- Catecholamines/metabolism
- Cell Line
- Dexamethasone/pharmacology
- Gene Expression Regulation/drug effects
- Gene Expression Regulation/immunology
- Glucocorticoids/pharmacology
- Humans
- Kinetics
- Monocytes/chemistry
- Monocytes/immunology
- Monocytes/metabolism
- Neurosecretory Systems/immunology
- RNA, Messenger/analysis
- Radioligand Assay
- Receptors, Adrenergic, alpha-1/analysis
- Receptors, Adrenergic, alpha-1/genetics
- Receptors, Adrenergic, alpha-1/metabolism
- Receptors, Adrenergic, beta/physiology
- Reverse Transcriptase Polymerase Chain Reaction
- Terbutaline/pharmacology
- Up-Regulation/immunology
Collapse
Affiliation(s)
- C Rouppe van der Voort
- Department of Immunology, University Hospital for Children and Youth Het Wilhelmina Kinderziekenhuis, Utrecht, The Netherlands.
| | | | | | | |
Collapse
|
6
|
Schneider GM, Lysle DT. Role of central mu-opioid receptors in the modulation of nitric oxide production by splenocytes. J Neuroimmunol 1998; 89:150-9. [PMID: 9726837 DOI: 10.1016/s0165-5728(98)00128-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Previous studies have shown that administration of morphine results in alterations of splenic macrophage nitric oxide production. The present studies were conducted to determine the subtype of opioid receptor involved in the modulation of macrophage nitric oxide production. Moreover, the present work was directed at determining whether nitric oxide production is regulated through opioid receptors in the central nervous system (CNS) or via opioid receptors found directly on splenocytes. The study shows that intracerebroventricular (i.c.v.) administration of the mu-selective opioid agonist, DAMGO, to rats dose-dependently increases the production of nitric oxide by splenocytes stimulated with toxic shock syndrome toxin (TSST-1). The effect of DAMGO is blocked by prior i.c.v. administration of N-methylnaltrexone. In contrast, i.c.v. administration of the kappa-selective agonist, U69,593, and the delta-selective agonist, DPDPE, have no significant effect on the production of nitric oxide. Furthermore, the in vitro administration of DAMGO, DPDPE, or U69,593 to splenocytes cultures does not significantly alter the production of nitric oxide by splenocytes. In addition, the present work shows that elevation of nitric oxide production by i.c.v. administration of DAMGO produces functional changes in splenic lymphocytes. Collectively, these results indicate that mu-opioid receptors within the CNS are involved in the regulation of splenic nitric oxide production.
Collapse
MESH Headings
- Analgesics/pharmacology
- Analgesics, Opioid/pharmacology
- Animals
- Bacterial Toxins
- Benzeneacetamides
- Cell Division/drug effects
- Cell Division/immunology
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/pharmacology
- Enterotoxins/pharmacology
- Enzyme Inhibitors/pharmacology
- Injections, Intraventricular
- Lymphocytes/cytology
- Lymphocytes/drug effects
- Male
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Narcotic Antagonists/pharmacology
- Neuroimmunomodulation/drug effects
- Neuroimmunomodulation/physiology
- Nitric Oxide/biosynthesis
- Nitric Oxide/immunology
- Nitric Oxide Synthase/antagonists & inhibitors
- Pyrrolidines/pharmacology
- Quaternary Ammonium Compounds
- Rats
- Rats, Inbred Lew
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/immunology
- Receptors, Opioid, mu/metabolism
- Spleen/cytology
- Spleen/enzymology
- Spleen/immunology
- Superantigens/pharmacology
- omega-N-Methylarginine/pharmacology
Collapse
Affiliation(s)
- G M Schneider
- Department of Psychology, University of North Carolina at Chapel Hill, 27599-3270, USA
| | | |
Collapse
|
7
|
Lysle DT, Coussons-Read ME. Mechanisms of conditioned immunomodulation. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1995; 17:641-7. [PMID: 8847158 DOI: 10.1016/0192-0561(95)00050-c] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
This article presents some recent work from our laboratory indicating that multiple physiological systems play a role in conditioned immunomodulation. The first study shows that naltrexone, but not N-methylnaltrexone, blocks the suppressive effects of an aversive conditioned stimulus on Con-A-induced proliferation and natural killer cell activity of splenic lymphocytes. This finding indicates that central opioid activity is involved in the conditioned effects. The second study shows that the beta-adrenergic antagonists atenolol and ICI-118,551 block of the suppressive effects of an aversive conditioned stimulus on Con-A-induced proliferation, but have no effect on natural killer cell activity. This result indicates the involvement of the adrenergic system in a subset of the conditioned effects. Collectively, these experiments provide evidence that both the opioid system and the sympathetic nervous system are involved in conditioned immunomodulatory changes elicited by an aversive conditioned stimulus.
Collapse
Affiliation(s)
- D T Lysle
- Department of Psychology, University of North Carolina at Chapel Hill 27599-3270, USA
| | | |
Collapse
|
8
|
Sanders VM. The role of adrenoceptor-mediated signals in the modulation of lymphocyte function. ADVANCES IN NEUROIMMUNOLOGY 1995; 5:283-98. [PMID: 8748072 DOI: 10.1016/0960-5428(95)00019-x] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Adrenoceptors are heterotrimeric glycoproteins that bind specific endogenous ligands, such as the sympathetic neurotransmitter norepinephrine and the neurohormone epinephrine. Ligand binding to an adrenoceptor expressed on the cell surface initiates a cascade of biochemical and molecular responses inside the cell that lead to a change in cellular activity. Initially, the stimulation of an adrenoceptor directly activates G proteins that stimulate enzymes to induce the production of second messengers. The cascade continues as the second messengers activate serine/threonine protein kinases, resulting in either an inhibition or enhancement of cellular activity. The resulting changes in cellular activity are mediated by changes in gene expression that are induced by the phosphorylation of specific transcription factors. Adrenoceptor subtypes are expressed by both T and B lymphocytes. The aim of this review is to summarize and discuss the results from the many studies that have examined the role of adrenoceptor-mediated intracellular signals in the modulation of lymphocyte function. Another aim of this review is to discuss how these studies have advanced our understanding of the mechanisms by which the sympathetic nervous system transmits information to both T and B lymphocytes to maintain immune homeostasis.
Collapse
Affiliation(s)
- V M Sanders
- Department of Cell Biology, Neurobiology and Anatomy, Loyola University of Chicago, Stritch School of Medicine, Maywood, IL 60153, USA
| |
Collapse
|
9
|
Erdtsieck-Ernste EB, Feenstra MG, Botterblom MH, De Barrios J, Boer GJ. Changes in adrenoceptors and monoamine metabolism in neonatal and adult rat brain after postnatal exposure to the antihypertensive labetalol. Br J Pharmacol 1992; 105:37-44. [PMID: 1596689 PMCID: PMC1908619 DOI: 10.1111/j.1476-5381.1992.tb14207.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
1. The purpose of the present study was to investigate the acute (single injection), direct (chronic treatment) and the long-lasting effects after exposure to the alpha 1/beta-adrenoceptor antagonist labetalol during rat brain development on adrenoceptors and monoamine metabolism. 2. In 10-day-old rat pups, subcutaneously administered labetalol (10 mg kg-1) passed the blood-brain barrier, reaching a level of 2.1 micrograms g-1 tissue in the brain 90 min after injection. 3. Chronic labetalol treatment (10 mg kg-1, s.c., twice daily) during the first 10 days of life significantly increased alpha 1-adrenoceptor binding in the hypothalamus (+39%), but not in the occipital cortex. 4. This chronic postnatal labetalol treatment did not result in long-lasting changes in alpha 1- and beta-receptors measured on day 60. 5. A single labetalol injection (10 mg kg-1, s.c.) on postnatal day 10 significantly increased noradrenaline (NA) metabolism in all brain regions tested (+25 to 105%), but had no effects on 5-hydroxytryptamine (5-HT) or dopamine metabolism. 6. Chronic labetalol treatment between postnatal (PN) days 1 and 10 also increased NA metabolism on PN 10 (3-methoxy-4-hydroxyphenylglycol (MHPG)/NA, +20 to 100%), suggesting that tolerance to the acute effect of labetalol did not occur. A slight increase in 5-HT metabolism (20%) was induced by the chronic labetalol treatment in the hippocampus and meso-limbic system. 7. In general, long-lasting effects on NA metabolism could not be detected on day 60 more than one month after the treatment. However, 5-HT metabolism was significantly increased in all four brain regions measured (+20 to 70%). 8. We conclude that chronic labetalol exposure during early postnatal rat brain development does not cause long-lasting changes in beta-receptor number or NA metabolism, but appears to be critical for the rate of 5-HT metabolism in later life.
Collapse
|
10
|
Goin JC, Sterin-Borda L, Borda ES, Finiasz M, Fernández J, de Bracco MM. Active alpha 2 and beta adrenoceptors in lymphocytes from patients with chronic lymphocytic leukemia. Int J Cancer 1991; 49:178-81. [PMID: 1652566 DOI: 10.1002/ijc.2910490205] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A single population of alpha 2 adrenoceptors was characterized in intact B lymphocytes from patients with chronic lymphocytic leukemia (B-CLL) by binding and saturation studies with 3H labelled yohimbine and by competition studies with alpha adrenergic antagonists. While the affinity of B-CLL alpha 2 adrenoceptors was low (KD: 9.81 nM-20.98 nM), each cell expressed a large number of receptors. No binding of the alpha 1 adrenoceptor antagonist prazosin was observed and the binding properties of beta adrenergic receptors (assayed with 3H-labelled dihydroalprenolol), were similar to those described for normal lymphocytes. Reaction of B-CLL with the beta adrenergic agonist isoproterenol raised the levels of cAMP in 11/13 patients tested, and in 8 of these, incubation with the alpha 2 adrenergic agonist clonidine prevented the effect and reduced the basal cAMP levels. The presence of active alpha 2 adrenoceptors on B-CLL lymphocytes may be involved in the regulation of metabolic pathways that affect cell functions and favor neoplastic growth.
Collapse
Affiliation(s)
- J C Goin
- Centro de Farmacología y Botánica CEFYBO, Buenos Aires, Argentina
| | | | | | | | | | | |
Collapse
|
11
|
Fuchs BA, McCall CO, Munson AE. Enhancement of the murine primary antibody response by phenylephrine in vitro. Drug Chem Toxicol 1991; 14:67-82. [PMID: 1653698 DOI: 10.3109/01480549109017869] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Phenylephrine was found to enhance the primary (immunoglobulin M) antibody response of murine splenocytes to sheep erythrocytes when added to splenocyte cultures at the time of in vitro immunization. The enhancement was seen at all times during the developing antibody response. One day after the peak response the enhancement was 78% above the control response, and was completely blocked by equimolar concentrations of the alpha adrenoceptor antagonist phentolamine. The alpha-1 adrenoceptor antagonist prazosin dose dependently antagonized the enhancement associated with phenylephrine one day after the peak response. These results suggest that phenylephrine prolongs the in vitro IgM antibody response by way of alpha-1 adrenoceptor activation. The adrenoceptors responsible for this pharmacologic response could not be demonstrated using direct radioligand binding techniques.
Collapse
Affiliation(s)
- B A Fuchs
- Department of Pharmacology and Toxicology, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298-0613
| | | | | |
Collapse
|
12
|
Goa KL, Benfield P, Sorkin EM. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs 1989; 37:583-627. [PMID: 2663413 DOI: 10.2165/00003495-198937050-00002] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Since labetalol was first reviewed in the Journal (1978), its scope of therapeutic use has expanded and become better defined. Labetalol is an adrenoceptor blocking drug with combined alpha- and beta-blocking properties. These result in a more favourable haemodynamic profile for labetalol compared with 'pure' beta-blockers or pure alpha-blockers, but also contribute to a wider range, but not an overall increased incidence, of adverse effects. The drug is effective and well-tolerated in patients with all grades of hypertension, but is of particular value in special subgroups such as Black patients, the elderly and patients with renal hypertension. While comparative studies are not extensive, available data show that the drug reduces blood pressure to a similar extent, and in a similar proportion of patients, as 'pure' beta-blockers such as propranolol, pure alpha-blockers such as prazosin, calcium antagonists (nifedipine, verapamil), and centrally acting drugs (clonidine and methyldopa). Labetalol is very effective in hypertensive pregnant women and in hypertensive crises, where it provides good control of blood pressure without serious adverse effects, and where few therapeutic options exist. Few controlled studies have investigated the use of labetalol in deliberate induction of hypotension or prevention of hypertension during anaesthesia, and also in patients with ischaemic heart disease. However, available evidence suggests a role for labetalol in these indications and further studies should aid in clarification of its efficacy in these areas. Thus, with its broad scope of therapeutic use in hypertension labetalol remains an important therapeutic option, and the drug may well find an additional place in the treatment of myocardial ischaemia if further evidence confirms encouraging preliminary findings.
Collapse
Affiliation(s)
- K L Goa
- ADIS Drug Information Services, Auckland, New Zealand
| | | | | |
Collapse
|
13
|
Abstract
Labetalol represents the culmination of an effort to enhance the antihypertensive efficacy and to improve the hemodynamic profile of beta-adrenoceptor blockers by incorporating an additional anti-hypertensive action, that is, alpha blockade, into its pharmacologic mechanism. Reviewed here are the major aspects of the animal pharmacology of labetalol. The compound blocks beta1 and beta2-adrenoceptors nonselectively. Its blockade of alpha receptors is selective and directed at the alpha1 subset. Labetalol also dilates blood vessels independently of these mechanisms. This action is mediated by activation of vascular beta2 adrenoceptors. Thus, labetalol acts as a partial agonist on vascular smooth muscle. However, it differs markedly from other beta blockers with intrinsic sympathomimetic activity in that its agonism is directed specifically at beta2 receptors. Labetalol lowers blood pressure in a variety of animal models of hypertension. Unlike pure beta blockers, the compound reduces peripheral vascular resistance. On the basis of this profile, it is proposed that labetalol lowers blood pressure in human subjects by three independent mechanisms: (1) beta blockade, (2) alpha blockade, and (3) direct vasodilatation.
Collapse
|
14
|
McPherson GA, Summers RJ. Evidence from binding studies for alpha 2-adrenoceptors directly associated with glomeruli from rat kidney. Eur J Pharmacol 1983; 90:333-41. [PMID: 6309533 DOI: 10.1016/0014-2999(83)90554-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Binding of the alpha 2-adrenoceptor radioligands [3H]clonidine and [3H]rauwolscine but not the alpha 1-adrenoceptor radioligand [3H]prazosin was enhanced in membranes prepared from rat isolated renal glomeruli. [3H]Rauwolscine binding to glomeruli was stereoselective with respect to the (-)-isomer of noradrenaline and the order of potency of a series of antagonists for displacement of binding indicated that the alpha 2-adrenoceptors in this preparation differ somewhat from those in some other species and tissues. Chemical sympathectomy produced no significant change in the number of sites labelled by [3H]rauwolscine indicating that few of the alpha 2-adrenoceptors in glomerular membranes are associated with sympathetic nerve terminals.
Collapse
|
15
|
POSTER COMMUNICATIONS. Br J Pharmacol 1983. [DOI: 10.1111/j.1476-5381.1983.tb17361.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|